Craft

Advanced
NeuroRx

NeuroRx

Stock Price

$1.3

2024-10-29

Market Capitalization

$13.7 M

2024-10-29

Revenue

$1.2 M

FY, 2025

NeuroRx Summary

Company Summary

Overview
NeuroRx is a clinical-stage pharmaceutical company. It is engaged in the development of NRX-101, an oral therapy for the treatment of acute suicidal behavior/ideation (ASIB) in bipolar disorder.
Type
Public
Status
Active
Founded
2015
HQ
Wilmington, DE, US | view all locations
Website
https://www.nrxpharma.com/
Cybersecurity rating
Sectors

Table of Contents

Key People

  • Dennis K. McBride, Chief Strategy Officer & Senior Scientist

    • Robert Besthof, Chief Commercial Officer

      • Jonathan C. Javitt, Chief Executive Officer, Chairman & Co-Founder

        • Daniel C. Javitt, Co-Founder and Chair, Scientific Advisory Board

          LocationsView all

          2 locations detected

          • Wilmington, DE HQ

            United States

            913 N Market St #200

          • Wilmington, DE

            United States

            1201 N Market St Suite 111-A

          NeuroRx Financials

          Summary Financials

          Revenue (Q1, 2026)
          $1.1M
          Gross profit (Q1, 2026)
          $469.0K
          Net income (Q1, 2026)
          ($1.4M)
          Cash (Q1, 2026)
          $6.7M
          EBIT (Q1, 2026)
          ($4.7M)
          Enterprise value
          $7.9M

          Competitors and Similar Companies

          Compare competitors

          Footer menu

          Product

          Solutions

          Resources

          Company

          © Craft.co 2026
          Share price data provided by IEX